We recently published a list of Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this ...

A combination messenger RNA vaccine against COVID-19 and seasonal influenza stacked up well against currently recommended vaccines in a phase 3 trial, according to findings published in JAMA.

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

A new vaccine that combines flu and COVID-19 protection in one shot shows promising results, but the U.S. Food and Drug ...

(Gray News) - A combination shot for flu and COVID-19 using messenger RNA-generated antibodies in a study, but U.S. government regulators want to see data on whether the new vaccine protects people ...

Moderna also hopes that combining the shots will help improve vaccine rates. Poland, however, is not sure people will like ...

The trial, which involved more than 8,000 adults 50 and older, found that antibody levels generated by the new vaccine were about 20% to 40% higher than getting the shots apart, with the exception of ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...

Moderna’s study, involving 8,000 adults 50 and older, showed the new combo shot generated an immune response against COVID and most strains of flu compared to existing stand-alone shots.

Sanofi trials new mRNA-based vaccine for facial acne Pharmaceutical company ... Others will receive a placebo—an inactive shot with no therapeutic effect. This comparison will help researchers measure ...

The vaccine's prospects were thrown into doubt after the FDA missed its April 1 deadline to approve the shot and Kennedy attributed ... offers an alternative to mRNA vaccines from Pfizer-BioNTech ...